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Summary
Colorectal cancer (CRC) is the third most common malignancy in the world. Thirty percent of all CRC cases are he-
reditary or familial forms of the disease. Approximately 5% of them represent well defined hereditary syndromes. Colon 
cancer syndromes are inherited autosomal dominant diseases, with exception of MUTYH associated polyposis, which is 
inherited in autosomal recessive manner. Most of CRC syndromes also carry significant risk of developing cancers of extra 
colonic localization.The clinician who deals with hereditary CRC patients should have a wide knowledge ofpresentation, 
genetics and cancer risks in hereditary CRC syndromes.In Croatia we donot have the center that systematically deals with 
CRC genetics, pharmacogenetics and hereditary CRC syndromes. Therefore, with this article, we systematically review the 
characteristics CRC syndromes.
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ONKOLO[KO SAVJETOVANJE BOLESNIKA I OBITELJI 
OBOLJELIH OD NASLJEDNOG KARCINOMA DEBELOG CRIJEVA
Sa`etak
Kolorektalni karcinom je tre}i naj~e{}i maligni tumor u svijetu. 30% slu~ajeva su nasljedni i familijarni oblici bolesti. 
Pribli`no 5% nasljednih oblika ~ine dobro definirani nasljedni sindromi kolorektalnog karcinoma.To su nasljedne autosom-
no dominantne bolesti, s izuzetkom tzv. MUTYH polipoze koja se naslje|uje autosomno recesivno. Ve}ina nasljednih sin-
droma kolorektalnog raka nosi rizik razvoja karcinoma drugih lokalizacija.Klini~ar koji sudjeluje u lije~enju oboljelih od 
kolorektalnog karcinoma trebao bi imati {iroko znanje o klini~koj slici, genetici i rizicima za pojedine tumore u nasljednim 
sindromima kolorektalnog raka.U Hrvatskoj jo{ uvijek nemamo centar koji bi se sustavno bavio genetikom kolorektalnog 
karcinoma, farmakogenetikom i nasljednim sindromima kolorektalnog raka. U ovom ~lanku donosimo pregled i karakteri-
stike nasljednih sindroma kolorektalnog raka.
KLJU^NE RIJE^I: nasljedni, kolorektalni karcinom, familijarna adenomatozna polipoza, Lynchev sindrom
INTRODUCTION
Colorectal cancer (CRC) is the third most 
common malignancy. Different studies confirmed 
that approximately 30% of all CRC cases are he-
reditary forms of the disease. Approximately 5% 
of them are associated with mutations of the genes 
that are highly penetrant and represent well de-
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fined syndromes. Etiology of the remaining 20-
30% is not well understood: cause being a muta-
tion in a single genes that regulate metabolism or 
environmental factors or the interplay of both.In 
this article, we review the characteristics of well 
known CRC syndromes. Although some similari-
ties do exist, they differ in clinical presentation, 
genetics and cancer risks. Identification of crucial 
genes improved the understanding of molecular 
mechanisms of CRC (1-3). The accumulation of 
genetic data required a clinician to interpret this 
data and out them into clinical context- their role 
in multidisciplinary colorectal cancer manage-
ment is gaining weight.
LYNCH SYNDROME
Lynch syndrome accounts for 2-4% of all he-
reditary CRC syndromes. Patients with Lynch 
syndrome are prone to various malignancies, pre-
dominantly colon and endometrial. Colon polyp-
osis is possible but not common. The lifetime risk 
of developing CRC is 50-80%. Lesions in Lynch 
syndrome have more proximal location compar-
ing to sporadic cases. They are also characterized 
by a high level of microsatellite instability (MSI), 
that is a feature of DNA mismatch repair (MMR) 
genes. Cancers with MSI have better prognosis 
than those without it.
Endometrial cancer is the most common ma-
lignancy outside the colon. Other include ovarian, 
gastric, ovarian, biliary small bowel, urinary tract, 
brain and pancreatic.
Lynch syndrome is the result of mutations in 
genes of DNA MMR that are important for ge-
nomic stability. These genes include hMSH2, 
hMLH1, hMSH6, and hPMS2. Of all Lynch syn-
drome cases, 90% are in hMSH2 and hMLH1 
genes. Mutations in hMSH6 account for approxi-
mately 10%. Recently, mutations in the EpCAM 
(epithelial cell adhesion molecule) gene, also 
known as TACSTD1, were found in somefamilies 
with Lynch syndrome. In these families malignan-
cies were with early onset and with multiple tu-
mors.
To diagnose Lynch syndrome it is important 
to take a detailed family history. Initially, Amster-
dam criteria I (Table 1) were developed to detect 
families that could have Lynch syndrome, but 50% 
of them failed to meet mentioned criteria. Im-
provement was made with Amsterdam II (Table 2) 
and Bethesda guidelines (Table 3). Families that fit 
these criteria require further evaluation. Genetic 
testing typically starts with analysis of hMLH1 
and hMSH2 genes, because they account for the 
majority of cases. This is the first approach that 
includes high costs and low sensitivity. The sec-
ond, cost-effective approach is to perform testing 
when any of the Bethesda guidelines are fulfilled. 
It begins with MSI and immunohistochemistry 
(IHC) analysis. Testing with IHC uses antibodies 
specific for hMLH1, hMSH2, hMSH6 and hPMS2 
proteins to evaluate tumors for MMR deficiency. 




Requires at least one of the following:
I.   CRC diagnosed in a patient who is less than 50 years 
of age
II.   Presence of synchronous, metachronous CRC, or other 
Lynch Syndrome -associated tumors, regardless of age
III.   CRC diagnosed in a patient who is less than 60 years 
of age with MSI-H histologyb IV. CRC diagnosed in an 
individual and one or more first degree relatives with an 
Lynch Syndrome -associated tumor, with at least one of 
the cancers being diagnosed under age 50 years
IV.   CRC diagnosed in an individual and two or more first or 
second degree relatives with Lynch Syndrome -associated 
tumors, regardless of age
Table 1.
AMSTERDAM CRITERIA I
At least three relatives with CRC; all of the following 
must be met:
I.   One affected individual is a first degree relative 
of the other two
II.  At least two successive generations affected
III.  At least one CRC diagnosed before the age of 50 years
IV.  Familial adenomatous polyposis has been excluded
Table 2.
AMSTERDAM CRITERIA II
At least three relatives with colorectal, endometrial, small 
bowel, ureter, or renal pelvis cancer; all of the following must 
be met:
I.  One affected individual is a first degree relative 
of the other two
II. At least two successive generations affected
III. At least one tumor diagnosed before the age of 50 years
IV. Familial adenomatous polyposis has been excluded
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Some models have recently been made to 
make a diagnosis of Lynch syndrome easier. They 
analyze the family history to estimate the proba-
bility that affected person carries MMR gene mu-
tation.
The fourth approach to diagnosis is to test all 
CRC and endometrial cancers to MMR deficiency 
and it has discovered that Bethesda guidelines still 
miss 28% of Lynch syndrome.
It is important to identify individuals with 
Lynch syndrome because surveillance decreases 
the incidence of tumors and related deaths. Regular 
colonoscopy should be performed at 1-2 year inter-
val, starting by age 20-25 years. When cancer ap-
pears, subtotal colectomy with ileorectal anastomo-
sis is advised and annual surveillance thereafter.
Prophylactic hysterectomy and bilateral sal-
pingo-oophorectomy is an option with women af-
ter completion of childbearing. Annual screening 
for these tumors is recommended after the age of 30 
and prophylactic surgery after the age of 40 (1-5).
FAMILIAL ADENOMATOUS POLYPOSIS
Familial adenomatous polyposis is the sec-
ond most common CRC syndrome with the carac-
teristic of developing numerous colon adenomas 
starting in early adolescence. If untreated, CRC is 
inevitable. 95% of patients with FAP develop CRC 
by the age of 50. Attenuated FAP is a less severe 
form of the disease with an average of 30 polyps, 
predominantly in proximal colon and a later age 
of CRC development. Gardner syndrome (FAP 
with epidermoid cysts, osteomas, dental anoma-
lies, and/or desmoid tumors), FAP and attenuat-
ed FAP are a result of APC gene mutations.
As an extra colonic feature of FAP upper gas-
trointestinal tract polyposis can occur. The lifetime 
risk of developing gastric cancer is 1% and of duo-
denal cancer 4-12%. Extra colonic features are less 
common in attenuated FAP.
If more than 100 colonic adenomas are identi-
fied, a diagnosis of FAP can be made. Younger 
people can have fewer polyps and might also have 
FAP. If more than 10 but less than 100 polyps are 
found in a person older than 40 to 50 years, a diag-
nosis of attenuated FAP can be made. FAP and at-
tenuated FAP are caused by alterations in APC 
gene that is tumor supressor gene. In 25% of FAP 
de novo mutations can be found.
Patients at risk for FAP or if a diagnosis of 
FAP is already established should have regular 
colonoscopy every 1-2 years starting at the age of 
10-12 years. Colectomy is performed when more 
than 20 adenomas develop, when they are more 
than 1 cm large or with malignant histology. If ad-
enomas are present in the anorectal region, muco-
sal stripping is done. If rectum is preserved, an-
nual endoscopic surveillance is necessary.
Individuals with attenuated FAP should have 
colonoscopy done every 1-2 years, starting before 
the age of 20 years.Regular 1-3years period upper 
GI tract endoscopy should be done in patients 
with FAP or attenuated FAP at the beginning of 
25-30 years. Patients with FAP also have an in-
creased risk for thyroid cancer (1,6).
MUTYH-ASSOCIATED POLYPOSIS
This syndrome is characterized by adenoma-
tous polyps of colorectal region and higher risk of 
CRC. Polyposis occurs at the age of 40. It is caused 
by mutations in MUTYH gene which product is 
involved in defending against oxidative damage 
of DNA. The diagnosis is made by genetic testing 
for specific MUTYH gene variants. Patients with 
this syndrome often have proximal colonic lesions 
and surveillance is started at the middle 20s. The 
risk for upper GI tract tumors is similar to that in 
FAP (1,3).
PEUTZ-JEGHERS SYNDROME (PJS) AND 
JUVENILE POLYPOSIS SYNDROME (JPS)
These syndromes are characterized with 
hamartomatous polyps and increased risk for 
CRC. People with PJS can be recognized by muco-
cutaneous pigmentations, typically present on the 
lips or buccal mucosa. These findings are absent in 
patients with JPS. The risk of developing breast 
and pancreatic cancer is also increased. Mucocuta-
neoustelangiectasias, GI arteriovenous malforma-
tions and pulmonary arterio-venous malforma-
tions can occur in 15% of patients with JPS. PJS is 
caused by mutations in STK11 gene, whereas JPS 
is caused by mutations in either SMAD4 or BM-
PR1A gene. Colonoscopy every 2–3 years is ad-
vised, beginning with symptoms or in late teens if 
no symptoms occur earlier (1,5).
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HYPERPLASTIC POLYPOSIS (HPP)
Its feature are multiple large hyperplastic 
polyps of the colon with unknown etiology. It has 
also increased risk of CRC, usually at the age of 50 
to 60 years. Lesions occur in the proximal colon. 
Rare familial cases of HPP have been reported. 
Regular colonoscopy every 1-2 years should be 
performed (1).
FAMILIAL COLORECTAL CANCER
30% of all CRC examples are inherited. Pa-
tients’ history and population studies revealed 
some less penetrant but more common suscepti-
bility genes. These cases are defined only by fam-
ily history. CRC risk associated with the common 
polymorphisms is affected by gene–gene and 
gene–environmental interactions. People who 
have a first-degree relative with CRC diagnosed 
over age 50 years have a 2–3-fold increased risk 
for this malignancy. In these cases, screening and 
surveillance are based on family history.
According to Jasperson et al. screening rec-
ommendations based on family history are as fol-
lows: 1) patients with a single first-degree relative 
over the age of 60 years with colon cancer should 
receive standard, average-risk colon cancer screen-
ing, but starting at age 40 years; 2) patients who 
have 1 relative with CRC under 60 years or 2 first-
degree relatives with CRC should be screened ev-
ery 5 years by colonoscopy, starting at age 40 
years, or at an age 10 years younger than the earli-
est case in the family; and 3) patients with only 
second- or third-degree relatives with CRC should 
receive average-risk screening.There are more 
than 170 low penetrance genetic variations that 
can confer susceptibility to CRC. These loci were 
discovered by single nucleotide polymorphism 
(SNP) markers and account for only 6% of CRC 
cases. Individual’s SNP profile can predict the risk 
of CRC an can be valuable to establish proper pre-
ventive measures (1,7-10).
ENVIRONMENTAL FACTORS
Environmental factors that are speculated to 
influence CRC risk in predisposed individuals. In 
fact aspirin, NSAIDs, selenium, calcium and folic 
acid were related to CRC risk, however the results 
of these studies are still debated. Recently, Zgaga 
et al. suggested causal relationship between 25-
hydroxyvitamin D and CRC. There are also differ-
ent alleles of CYP24A1 and CYP24B1 that affect 
colon cancer risk depending on vitamin D and cal-
cium intake, ultraviolet exposure, genderand es-
trogen replacement therapy. Nevertheless, further 
studies are needed to identify optimal strategy for 
CRC prevention by pharmacological intervention 
or dietary intake recommendation (11-13).
Genetic counseling
Genetic counseling is essential for interpret-
ing results of oncological genetic testing and giv-
ing their context. Across European Union, it has 
been performed by both nurses and the physi-
cians. The formation in genetic counseling EU var-
ies from courses to subspecialty after specialty in 
pediatrics of clinical medicine. Ideally, interpreta-
tion of the results and counseling should be at the 
same location, available at institution which spe-
cialize in cancer care (Fig. 1.).
Figure 1.
CONCLUSION
Colon cancer syndromes are inherited auto-
somal dominant diseases, with exception of MAP, 
which is inherited in autosomal recessive manner, 
and HPP, etiology is still not well understood. 
Analyses of CRC risk should be implemented in 
clinical practice; the most important step is de-
tailed family history taking and analysis. Individ-
uals with higher risk for CRC should get proper 
genetic counseling with adequate plan for future 
screening. Most of well defined CRC syndromes 
carry significant risk of developing cancer of extra 
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colonic location and the screening plan should 
take it into account.The clinician who takes care of 
CRC patient should have a wide knowledge of 
presentation, genetics and cancer risks in heredi-
tary CRC syndromes.
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